:: Main :: About :: Current Issue :: Archive :: Submit :: Contact ::
:: Volume 6, Issue 2 (12-2019) ::
vacres 2019, 6(2): 14-17 Back to browse issues page
Prospective on Different Approaches for Vaccine Development Against COVID-19: Past Lessons and Future Challenges
Pooneh Rhimi * , Mohammad Reza Aghasadeghi
Department of Hepatitis and AIDS, Pasteur Institute of Iran, Tehran, Iran
Abstract:   (130 Views)
Since the reemergence of a severe acute respiratory syndrome caused by a novel coronavirus (SARS-CoV-2), the disease caused by this virus, known as COVID-19, has been spreading rapidly all around the world. As of early June 2020, COVID-19 has infected more that 6.6 million people, and has caused more than 390,000 deaths, globally. Similar to its pioneers, namely SARS-CoV and MERS-CoV, there is currently no vaccine or specific antiviral treatment against this virus. This review provides a timely overview on efforts as well as different platforms used for developing an effective vaccine against COVID-19.
Keywords: SARS-CoV-2, COVID-19, Spike protein, subunit vaccines, COVID-19 vaccines
Full-Text [PDF 365 kb]   (66 Downloads)    
Type of Study: Review article | Subject: Vaccine development, efficacy and safety evaluation
Received: 2020/06/8 | Accepted: 2020/06/8 | Published: 2020/06/8
Send email to the article author

Add your comments about this article
Your username or Email:

CAPTCHA



XML     Print


Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Rhimi P, Aghasadeghi M R. Prospective on Different Approaches for Vaccine Development Against COVID-19: Past Lessons and Future Challenges. vacres. 2019; 6 (2) :14-17
URL: http://vacres.pasteur.ac.ir/article-1-194-en.html


Volume 6, Issue 2 (12-2019) Back to browse issues page
تحقیقات واکسن Vaccine Research
Persian site map - English site map - Created in 0.2 seconds with 33 queries by YEKTAWEB 4144
Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.